

# Tu'uhevaha J Kaitu'u-Lino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/590554/publications.pdf>

Version: 2024-02-01

107  
papers

2,879  
citations

136740

32  
h-index

214527

47  
g-index

107  
all docs

107  
docs citations

107  
times ranked

2977  
citing authors



#	ARTICLE	IF	CITATIONS
19	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1157-S1170.	0.7	47
20	Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. <i>BMJ, The</i> , 2021, 374, n2103.	3.0	46
21	Sofalcone Upregulates the Nuclear Factor (Erythroid-Derived 2)â€œLike 2/Heme Oxygenase-1 Pathway, Reduces Soluble fmsâ€œLike Tyrosine Kinase-1, and Quenches Endothelial Dysfunction. <i>Hypertension</i> , 2015, 65, 855-862.	1.3	44
22	Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. <i>Human Reproduction Update</i> , 2021, 27, 280-304.	5.2	42
23	Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E936-E945.	1.8	40
24	PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. <i>Reproduction, Fertility and Development</i> , 2014, 26, 351.	0.1	39
25	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. <i>EBioMedicine</i> , 2019, 41, 636-648.	2.7	38
26	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. <i>Nature Communications</i> , 2020, 11, 2411.	5.8	37
27	Identification of Label-Retaining Perivascular Cells in a Mouse Model of Endometrial Decidualization, Breakdown, and Repair1. <i>Biology of Reproduction</i> , 2012, 86, 184.	1.2	36
28	ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. <i>American Journal of Pathology</i> , 2018, 188, 1749-1753.	1.9	36
29	Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse. <i>Reproduction</i> , 2006, 132, 799-810.	1.1	34
30	A New Role for Activin in Endometrial Repair after Menses. <i>Endocrinology</i> , 2009, 150, 1904-1911.	1.4	34
31	Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. <i>PLoS ONE</i> , 2018, 13, e0187082.	1.1	34
32	A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol. <i>BMJ Open</i> , 2019, 9, e025809.	0.8	34
33	Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. <i>Pregnancy Hypertension</i> , 2020, 20, 83-91.	0.6	33
34	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. <i>Hypertension</i> , 2015, 66, 1073-1081.	1.3	32
35	Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. <i>Journal of Reproductive Immunology</i> , 2012, 95, 46-49.	0.8	31
36	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction â€œ implications for treating preeclampsia. <i>PLoS ONE</i> , 2018, 13, e0188845.	1.1	31

#	ARTICLE	IF	CITATIONS
37	The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. <i>Placenta</i> , 2019, 84, 28-31.	0.7	30
38	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. <i>Placenta</i> , 2020, 102, 10-16.	0.7	30
39	Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. <i>Human Reproduction</i> , 2013, 28, 1172-1180.	0.4	27
40	Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. <i>Hypertension</i> , 2017, 70, 1014-1024.	1.3	27
41	Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation. <i>PLoS ONE</i> , 2016, 11, e0163096.	1.1	27
42	Extracellular Matrix Dynamics in Scar-Free Endometrial Repair: Perspectives from Mouse In Vivo and Human In Vitro Studies. <i>Biology of Reproduction</i> , 2011, 85, 511-523.	1.2	26
43	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. <i>Molecular and Cellular Endocrinology</i> , 2015, 413, 202-208.	1.6	26
44	Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. <i>BMC Pregnancy and Childbirth</i> , 2018, 18, 354.	0.9	26
45	Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth. <i>Obstetrics and Gynecology</i> , 2013, 122, 737-744.	1.2	25
46	Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth. <i>BMC Medicine</i> , 2020, 18, 145.	2.3	25
47	Plasma MIC-1 and PAPP-A Levels Are Decreased among Women Presenting to an Early Pregnancy Assessment Unit, Have Fetal Viability Confirmed but Later Miscarry. <i>PLoS ONE</i> , 2013, 8, e72437.	1.1	22
48	Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 521.e1-521.e8.	0.7	21
49	Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation. <i>Reproductive Sciences</i> , 2015, 22, 852-859.	1.1	20
50	Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. <i>Placenta</i> , 2017, 51, 1-9.	0.7	20
51	Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. <i>Placenta</i> , 2014, 35, 1106-1109.	0.7	19
52	MT-MMPs in pre-eclamptic placenta: Relationship to soluble endoglin production. <i>Placenta</i> , 2013, 34, 168-173.	0.7	18
53	MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin. <i>PLoS ONE</i> , 2012, 7, e39864.	1.1	17
54	A Bioplex Analysis of Cytokines and Chemokines in First Trimester Maternal Plasma to Screen for Predictors of Miscarriage. <i>PLoS ONE</i> , 2014, 9, e93320.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production. <i>Biology of Reproduction</i> , 2016, 94, 59.	1.2	17
56	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. <i>Journal of the American Heart Association</i> , 2021, 10, e020302.	1.6	17
57	The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women. <i>Reproduction</i> , 2007, 133, 309-321.	1.1	16
58	ATF3 is a negative regulator of inflammation in human fetal membranes. <i>Placenta</i> , 2016, 47, 63-72.	0.7	15
59	Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. <i>Prenatal Diagnosis</i> , 2019, 39, 947-957.	1.1	15
60	Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. <i>Pregnancy Hypertension</i> , 2020, 22, 86-92.	0.6	15
61	Serum Concentrations of Soluble Flt-1 Are Decreased among Women with a Viable Fetus and No Symptoms of Miscarriage Destined for Pregnancy Loss. <i>PLoS ONE</i> , 2012, 7, e32509.	1.1	14
62	Evaluation of ADAM-12 as a Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. <i>PLoS ONE</i> , 2012, 7, e41442.	1.1	13
63	Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 635-639.	0.7	13
64	Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production by First-Trimester Placental Explants Following Myostatin Treatment. <i>Reproductive Sciences</i> , 2015, 22, 1202-1211.	1.1	12
65	Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. <i>Placenta</i> , 2016, 48, 110-118.	0.7	12
66	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. <i>Placenta</i> , 2020, 95, 78-83.	0.7	12
67	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. <i>Reproductive Sciences</i> , 2017, 24, 1245-1252.	1.1	11
68	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. <i>Pregnancy Hypertension</i> , 2019, 16, 16-25.	0.6	11
69	MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia. <i>Scientific Reports</i> , 2020, 10, 18077.	1.6	11
70	Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives. <i>Reproduction</i> , 2008, 136, 267-274.	1.1	10
71	Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. <i>Placenta</i> , 2015, 36, 932-937.	0.7	9
72	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. <i>Placenta</i> , 2019, 87, 53-57.	0.7	9

#	ARTICLE	IF	CITATIONS
73	Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia. <i>Placenta</i> , 2019, 88, 1-7.	0.7	9
74	Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. <i>Placenta</i> , 2020, 91, 24-30.	0.7	9
75	Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7467.	1.8	9
76	Analysis of mitochondrial regulatory transcripts in publicly available datasets with validation in placentae from pre-term, post-term and fetal growth restriction pregnancies. <i>Placenta</i> , 2021, 112, 162-171.	0.7	9
77	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. <i>Placenta</i> , 2016, 48, 72-79.	0.7	9
78	sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?. <i>Pregnancy Hypertension</i> , 2017, 10, 18-21.	0.6	8
79	Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 13, 1-6.	0.6	8
80	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. <i>Scientific Reports</i> , 2019, 9, 235.	1.6	8
81	Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. <i>Placenta</i> , 2021, 105, 32-40.	0.7	8
82	DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia. <i>Scientific Reports</i> , 2021, 11, 5540.	1.6	8
83	Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. <i>Reproductive Biology and Endocrinology</i> , 2013, 11, 40.	1.4	7
84	Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction. <i>Placenta</i> , 2020, 95, 53-61.	0.7	7
85	Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study. <i>Placenta</i> , 2021, 110, 24-28.	0.7	7
86	A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeksâ€™ gestation in pregnancies destined to deliver small for gestational age infants. <i>Placenta</i> , 2022, 117, 1-4.	0.7	7
87	Placental SEMA3B expression is not altered in severe early onset preeclampsia. <i>Placenta</i> , 2014, 35, 1102-1105.	0.7	6
88	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. <i>Pregnancy Hypertension</i> , 2016, 6, 95-102.	0.6	6
89	EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 14, 115-120.	0.6	6
90	Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. <i>PLoS ONE</i> , 2013, 8, e66339.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia. <i>Journal of Clinical Medicine</i> , 2021, 10, 3384.	1.0	5
92	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. <i>Scientific Reports</i> , 2021, 11, 16595.	1.6	5
93	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. <i>Placenta</i> , 2021, 114, 22-28.	0.7	5
94	PSG7 and 9 (Pregnancy-specific Î²â€ Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia. <i>Journal of the American Heart Association</i> , 2022, 11, e024536.	1.6	5
95	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. <i>EBioMedicine</i> , 2018, 29, 166-176.	2.7	4
96	Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction. <i>Journal of Clinical Medicine</i> , 2022, 11, 901.	1.0	4
97	Circulating Activin A is elevated at 36 weeks gestation preceding a diagnosis of preeclampsia. <i>Pregnancy Hypertension</i> , 2022, 27, 23-26.	0.6	3
98	A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid. <i>BMC Research Notes</i> , 2016, 9, 335.	0.6	2
99	LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast. <i>Pregnancy Hypertension</i> , 2021, 25, 255-261.	0.6	2
100	Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 501-503.	0.7	1
101	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. <i>Pregnancy Hypertension</i> , 2018, 14, 125-130.	0.6	1
102	NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast. <i>Scientific Reports</i> , 2021, 11, 20670.	1.6	1
103	Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies. <i>American Journal of Obstetrics &amp; Gynecology MFM</i> , 2022, 4, 100618.	1.3	1
104	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. <i>Pregnancy Hypertension</i> , 2014, 4, 255-258.	0.6	0
105	A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin. <i>Pregnancy Hypertension</i> , 2015, 5, 294-297.	0.6	0
106	Screening circulating proteins to identify biomarkers of fetal macrosomia. <i>BMC Research Notes</i> , 2019, 12, 587.	0.6	0
107	Measuring circulating miRNAs in early pregnancy could identify fetuses destined to undergrow and be at increased risk of stillbirth. <i>EBioMedicine</i> , 2021, 63, 103172.	2.7	0